Supplementary Figure 11 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Multivariable analysis of OS and PFS using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a bespoke targeted approach across the trial cohort. At both baseline and cycle 3, patients were split into above- or below-median groups. Survival outcomes are shown in a multivariable analysis including cohort, PD-L1 expression, and tumor mutation burden (TMB).